Rhythm Pharmaceuticals
RYTM
165 hedge funds and large institutions have $2.85B invested in Rhythm Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 63 increasing their positions, 54 reducing their positions, and 24 closing their positions.
84% more call options, than puts
Call options by funds: $20.3M | Put options by funds: $11M
17% more repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 54
0.54% more ownership
Funds ownership: 113.12% → 113.66% (+0.54%)
0% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 24
3% less capital invested
Capital invested by funds: $2.95B → $2.85B (-$99.9M)
1% less funds holding
Funds holding: 167 → 165 (-2)
11% less funds holding in top 10
Funds holding in top 10: 9 → 8 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alkeon Capital Management
New York
|
+$39.9M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$30.1M |
| 3 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$13M |
| 4 |
Morgan Stanley
New York
|
+$11.7M |
| 5 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$10.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$40.3M |
| 2 |
Primecap Management
Pasadena,
California
|
-$17.4M |
| 3 |
Pictet Asset Management
Carouge,
Switzerland
|
-$16.4M |
| 4 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$9.68M |
| 5 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$7.13M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
176
D.E. Shaw & Co
New York
| – | -$453K | -10,462 | Closed |
|
|
EFM
177
E Fund Management
Guangzhou,
China
| – | -$448K | -10,333 | Closed |
|
|
ACM
178
Aquatic Capital Management
Chicago,
Illinois
| – | -$373K | -8,600 | Closed |
|
179
Allianz Asset Management
Munich,
Germany
| – | -$321K | -7,400 | Closed |
|
180
Capstone Investment Advisors
New York
| – | -$292K | -6,738 | Closed |
|
|
AIM
181
Aigen Investment Management
New York
| – | -$281K | -6,479 | Closed |
|
182
Citadel Advisors
Miami,
Florida
| – | -$164K | -4,098 | Closed |
|
|
QT
183
Quantbot Technologies
New York
| – | -$156K | -3,600 | Closed |
|
|
MLICM
184
Metropolitan Life Insurance Company (MetLife)
New York
| – | -$122K | -2,812 | Closed |
|
185
Lazard Asset Management
New York
| – | -$75K | -1,733 | Closed |
|
|
FIM
186
Fernwood Investment Management
Quincy,
Massachusetts
| – | -$67.3K | -1,554 | Closed |
|
|
TC
187
Truvestments Capital
Sarasota,
Florida
| – | -$9.36K | -216 | Closed |
|
|
AWM
188
Avior Wealth Management
Omaha,
Nebraska
| – | -$433 | -10 | Closed |
|
RYTM Hedge Fund Activity: Q2 2024 in Review
165 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Rhythm Pharmaceuticals (RYTM) for Q2 2024, worth a combined $2.85B — down 3.4% from $2.95B a quarter earlier.
Fund positioning in RYTM was balanced in Q2 2024: 24 funds opened new positions, 24 closed out, 63 added to existing stakes and 54 trimmed.
The largest buyer was Alkeon Capital Management, opening a new position worth an estimated $39.9M. The largest seller was State Street, cutting an estimated $40.3M.
- 165 institutional investors held Rhythm Pharmaceuticals (RYTM) as of Q2 2024, down from 167 in Q1 2024.
- Funds reported $2.85B of Rhythm Pharmaceuticals stock for Q2 2024, down 3.4% quarter-over-quarter.
- 24 funds opened new Rhythm Pharmaceuticals positions in Q2 2024 and 24 closed out, a net change of 0 holders.
- The largest Rhythm Pharmaceuticals buyer in Q2 2024 was Alkeon Capital Management, an estimated $39.9M added.
- The largest Rhythm Pharmaceuticals seller in Q2 2024 was State Street, an estimated $40.3M sold.
Based on aggregated 13F filings for Q2 2024.